A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) (NCT07221500)

🧪 Interventions in This Study

• NX-5948 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (37 Sites)

Showing the first 25 of 37 sites.

• City of Hope — Duarte, California
• Cedars-Sinai Medical Center — Los Angeles, California
• Scripps Health — San Diego, California
• Colorado Blood Institute — Denver, Colorado
• University of Miami — Coral Gables, Florida
• Florida Cancer Specialists — Sarasota, Florida
• Fort Wayne Oncology and Hematology — Fort Wayne, Indiana
• Hematology Oncology of Indiana — Indianapolis, Indiana
• University of Iowa — Iowa City, Iowa
• Maryland Oncology Hematology — Silver Spring, Maryland
• Karmanos Cancer Center — Detroit, Michigan
• Duke University — Durham, North Carolina
• Novant Health Cancer Institute — Winston-Salem, North Carolina
• University of Cincinnati — Cincinnati, Ohio
• The Cleveland Clinic Foundation — Cleveland, Ohio
• The Ohio State University — Columbus, Ohio
• Oncology Hematology Care — Fairfield, Ohio
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• SCRI Oncology Partners — Nashville, Tennessee
• Texas Oncology - Center South — Austin, Texas
• University of Utah — Salt Lake City, Utah
• Virginia Cancer Specialists, PC — Fairfax, Virginia
• Oncology & Hematology Associates of Southwest VA — Norfolk, Virginia
• Virginia Oncology Associates — Norfolk, Virginia
• Fred Hutchinson Cancer Center — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (415) 417-3418

Email: clinicaltrials@nurixtx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia (CLL)

• The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) — Stanford, California
• Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax — Basking Ridge, New Jersey
• A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies — New York, New York
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Stamford, Connecticut
• A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — Houston, Texas
• Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Bethesda, Maryland

Explore by condition: All Chronic Lymphocytic Leukemia (CLL) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.